Flurbiprofen cataplasm

A flurbiprofen and filler technology, which is applied in the field of external preparations of non-steroidal anti-inflammatory drugs, can solve the problems of long-acting time, uneven drug release rate, slow transdermal absorption rate, etc.

Active Publication Date: 2017-05-17
北京茗泽中和药物研究有限公司
View PDF5 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Chinese patent CN031164412 discloses a kind of flurbiprofen cataplasm, and discloses a plurality of prescriptions, after testing, we find that the specific prescriptions disclosed in this document all have the defects of slow transdermal absorption rate and uneven drug release rate , the advantages of fast onset of action and long duration of action of the cataplasm cannot be repeated

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Flurbiprofen cataplasm
  • Flurbiprofen cataplasm
  • Flurbiprofen cataplasm

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Pharmacological Example 1 In Vitro Release Experiment

[0023] According to the third method (paddle and disk method, used for transdermal patches) in the release assay method in the second appendix XD of the Chinese Pharmacopoeia 2010 edition, the emergency release assay of the cataplasma obtained in Examples 3 and 4 was performed. The specific method is as follows

[0024] The test uses physiological saline as the release medium: add the release medium to the dissolution cup, pre-warm to (32±0.5°C), remove the protective layer from the cataplasm, cut it into a size of 2.5cmx7.5cm, and put it flat into the dialysis bag (MWCO 14,000), the release side faces up, and placed between two layers of discs, so that the edges of the disc clamp the two ends of the dialysis bag, and then wrap and fix with rubber bands to fix the disc. Take 6mL samples from the dissolution vessel at 10min, 20min, 30min, 45min, 60min, 90min, 2h, 2.5h, 3h and 4h respectively, and add an equal volum...

Embodiment 2

[0025] Pharmacological embodiment 2, in vitro transdermal experiment

[0026] Using the improved Franz diffusion cell method, using the abdominal skin of the isolated 3-month-old rat as a barrier, the cataplasms prepared in Examples 3 and 4 and the commercially available flurbiprofen cataplasm (as a positive control) were used for in vitro Transdermal test. The specific experimental method is:

[0027] After 3-month-old healthy rats were anesthetized and killed, the abdominal hair was removed with scissors, the undamaged skin was removed, and the subcutaneous tissue was removed. After washing, they were respectively fixed at the release port of the Franz diffusion cell, and pH 7.4 phosphoric acid was added to the receiving chamber. The buffer is used as a release medium to keep the endothelial layer in close contact with the solution. Put the cataplasm with the protective layer removed on the skin, adjust the water bath so that the temperature of the outer layer is constant ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a flurbiprofen cataplasm, which consists of a backing layer, a medicament storage space and a protective layer, wherein the medicament storage space consists of the following components in percentage by weight: 0.2 to 0.5 percent of flurbiprofen serving as an active ingredient, 5 to 10 percent of an oil-phase component, 5 to 10 percent of partial neutralization sodium polyacrylate, 20 to 40 percent of a humectant, 0.5 to 1.5 percent of carbomer 980, 1.5 to 3 percent of CMC-Na (sodium carboxymethyl cellulose), 0.2 to 0.4 percent of dihydroxyaluminium aminoacetate, 0.1 to 0.3 percent of EDTA-2Na (disodium ethylene diamine tetraacetic acid, 0.5 to 0.7 percent of tween 80, 1 to 3 percent of a filler and the balance of water, wherein the oil-phase component is prepared from caprin, oleic acid and peregal A-20 in a mass ratio of 1:(0.2 to 0.3):(0.2 to 0.3), and the partial neutralization sodium polyacrylate, the humectant, the carbomer 980, the CMC-Na, the dihydroxyaluminium aminoacetate, the EDTA-2Na and the tween 80 form a water-phase component.

Description

technical field [0001] The invention relates to an external preparation of a non-steroidal anti-inflammatory drug, in particular to a cataplasm. Background technique [0002] The molecular formula of flurbiprofen (CAS: 51543-40-9, flurbiprofen) is as follows: [0003] [0004] Flurbiprofen is a fluorine-containing non-steroidal anti-inflammatory drug, mainly used in the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, traumatic pain and other pain. Flurbiprofen acts as an anti-inflammatory and analgesic by inhibiting the activity of prostaglandin synthase cyclooxygenase. Compared with oral administration, when used for pain caused by trauma and inflammation of joints, soft tissues, and muscles, the use of external preparations can reduce the side effects of oral administration and accelerate the onset of the drug. [0005] Cataplasm refers to a new type of transdermal dosage form in which drugs are dissolved or mixed in a water-soluble polymer ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/70A61K31/192A61K47/12A61K47/26A61P29/00
CPCA61K9/7061A61K31/192A61K47/12A61K47/26
Inventor 杨红伟姚永波李斐菲
Owner 北京茗泽中和药物研究有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap